|
|
|
Kevin Buckley |
|
Partner |
|
St. Louis, Missouri |
|
 |
 |
Kevin Buckley is the leader of our Life Sciences Practice. His practice is focused on the intersection of business, science, and multiple areas of the law as it relates to biotechnology, life sciences, and pharmaceutical commercialization. He has over a decade of experience representing prominent multinational corporations, private research institutes, university systems, trade associations, patient advocacy and disease organizations, start-up companies, investors, and individual entrepreneurs. His practice particularly emphasizes intellectual property portfolio management, patent opinion drafting, pharmaceutical and biopharmaceutical life-cycle strategy, and complex transactions relating to drug and biological product licenses, acquisit... » Read More Kevin Buckley is the leader of our Life Sciences Practice. His practice is focused on the intersection of business, science, and multiple areas of the law as it relates to biotechnology, life sciences, and pharmaceutical commercialization. He has over a decade of experience representing prominent multinational corporations, private research institutes, university systems, trade associations, patient advocacy and disease organizations, start-up companies, investors, and individual entrepreneurs. His practice particularly emphasizes intellectual property portfolio management, patent opinion drafting, pharmaceutical and biopharmaceutical life-cycle strategy, and complex transactions relating to drug and biological product licenses, acquisitions, company alliances, and investments.
Kevins experience on several litigation teams includes successfully obtaining final judgments or settling patent infringement, trademark infringement, copyright infringement, unfair competition, and trade secret claims. In addition, he has experience with successfully resolving patent interferences. Prior to becoming an attorney, he was involved with the founding of several start-up ventures that provides him particular insight into the larger business and operational context for issues faced by both emerging and mature businesses.
He also represents clients with respect to public policy matters. This representation includes drafting and analyzing legislation pending before the U.S. Congress and the Missouri legislature related to economic development, stem cell technologies, and elementary and secondary education. He was Legislative Counsel for the Missouri Biotechnology Association from 2001 to 2005.
Kevin was a biochemist in both academics and industry for six years when he investigated and assisted in commercializing ribonucleic acid (RNA)-based therapeutics for treating viral infections and purine nucleoside analogs for treating autoimmune diseases and cytokine mediated cell responses in apoptosis, autoimmune diseases, AIDS, and cancers.
Kevin received a J.D. from the University of Pittsburgh where he was the Editor-in-Chief of The Pittsburgh Journal of Technology Law & Policy, and received a B.S. in Biochemistry from the University of California, San Diego where he was a Research Scholar.
In 2005, Kevin was named one of St. Louis Business Journal's "40 Under Forty," an annual award for becoming "a mover and shaker both in business and the St. Louis community." He is listed in Who's Who in America, Who's Who in the World, and Who's Who in American Law. Kevin was also selected as a member of "Who's Who in Technology" by the St. Louis Business Journal in 2007. Most recently, he was appointed to the State of Missouri Intellectual Property Management Fund which funds intellectual property protection for local innovators.
Kevin is a member of the Missouri Biotechnology Association, the International Society for Stem Cell Research, and the St. Louis Regional Chamber and Growth Association Plant and Life Science Network. He is a registered patent attorney with the U.S. Patent & Trademark Office and is admitted to practice law in Missouri.
» Read Less Kevin Buckley is the leader of our Life Sciences Practice. His practice is focused on the intersection of business, science, and multiple areas of the law as it relates to biotechnology, life sciences, and pharmaceutical commercialization. He has over a decade of experience representing prominent multinational corporations, private research institutes, university systems, trade associations, patient advocacy and disease organizations, start-up companies, investors, and individual entrepreneurs. His practice particularly emphasizes intellectual property portfolio management, patent opinion drafting, pharmaceutical and biopharmaceutical life-cycle strategy, and complex transactions relating to drug and biological product licenses, acquisitions, company alliances, and investments.
Kevins experience on several litigation teams includes successfully obtaining final judgments or settling patent infringement, trademark infringement, copyright infringement, unfair competition, and trade secret claims. In addition, he has experience with successfully resolving patent interferences. Prior to becoming an attorney, he was involved with the founding of several start-up ventures that provides him particular insight into the larger business and operational context for issues faced by both emerging and mature businesses.
He also represents clients with respect to public policy matters. This representation includes drafting and analyzing legislation pending before the U.S. Congress and the Missouri legislature related to economic development, stem cell technologies, and elementary and secondary education. He was Legislative Counsel for the Missouri Biotechnology Association from 2001 to 2005.
Kevin was a biochemist in both academics and industry for six years when he investigated and assisted in commercializing ribonucleic acid (RNA)-based therapeutics for treating viral infections and purine nucleoside analogs for treating autoimmune diseases and cytokine mediated cell responses in apoptosis, autoimmune diseases, AIDS, and cancers.
Kevin received a J.D. from the University of Pittsburgh where he was the Editor-in-Chief of The Pittsburgh Journal of Technology Law & Policy, and received a B.S. in Biochemistry from the University of California, San Diego where he was a Research Scholar.
In 2005, Kevin was named one of St. Louis Business Journal's "40 Under Forty," an annual award for becoming "a mover and shaker both in business and the St. Louis community." He is listed in Who's Who in America, Who's Who in the World, and Who's Who in American Law. Kevin was also selected as a member of "Who's Who in Technology" by the St. Louis Business Journal in 2007. Most recently, he was appointed to the State of Missouri Intellectual Property Management Fund which funds intellectual property protection for local innovators.
Kevin is a member of the Missouri Biotechnology Association, the International Society for Stem Cell Research, and the St. Louis Regional Chamber and Growth Association Plant and Life Science Network. He is a registered patent attorney with the U.S. Patent & Trademark Office and is admitted to practice law in Missouri.
|
|
Representative Technologies |
|
Representative technologies with which Kevin has assisted clients include: biopharmaceuticals, small molecule pharmaceuticals, and biologics (e.g., therapeutic polynucleotides and polypeptides including siRNA, shRNA, miRNA, ribozymes, antisense DNA, antibodies, related fragments, vaccines, and enzymes); RNA interference (RNAi); medical imaging compounds and diagnostic methods; polynucleotide and polypeptide detection and screening; bioinformatics; structural proteomics; three-dimensional molecular modeling and drug design; stem cells and therapeutic cloning methods; transgenic plants and animals; microorganism/cell culture equipment and methods; biofuels and agriculture biotechnologies; and wet and dry nanotechnologies.
Representative technologies with which Kevin has assisted clients include: biopharmaceuticals, small molecule pharmaceuticals, and biologics (e.g., therapeutic polynucleotides and polypeptides including siRNA, shRNA, miRNA, ribozymes, antisense DNA, antibodies, related fragments, vaccines, and enzymes); RNA interference (RNAi); medical imaging compounds and diagnostic methods; polynucleotide and polypeptide detection and screening; bioinformatics; structural proteomics; three-dimensional molecular modeling and drug design; stem cells and therapeutic cloning methods; transgenic plants and animals; microorganism/cell culture equipment and methods; biofuels and agriculture biotechnologies; and wet and dry nanotechnologies.
»Read Less |
|
Representative technologies with which Kevin has assisted clients include: biopharmaceuticals, small molecule pharmaceuticals, and biologics (e.g., therapeutic polynucleotides and polypeptides including siRNA, shRNA, miRNA, ribozymes, antisense DNA, antibodies, related fragments, vaccines, and enzymes); RNA interference (RNAi); medical imaging compounds and diagnostic methods; polynucleotide and polypeptide detection and screening; bioinformatics; structural proteomics; three-dimensional molecular modeling and drug design; stem cells and therapeutic cloning methods; transgenic plants and animals; microorganism/cell culture equipment and methods; biofuels and agriculture biotechnologies; and wet and dry nanotechnologies.
|
|
Presentations and Publications |
BioCommercialization, a resource for professionals who translate research innovations into developed products available at biocommercialization.com.
Presenter, ABCs of Commercialization, 6th Corn Utilization and Technology Conference, Kansas City, Missouri (June 3, 2008).
Presenter, Opportunities in Emerging Geographies, 2nd Annual Global Healthcare Investing Conference, Cleveland, Ohio (April 30, 2008).
Interviewed for feature segment related to biotechnology commercialization and pharmaceutical commercialization, Conversation with Lee Presser (television broadcast September 10 & 17, 2007).
Presenter, Bringing Overseas Start-Ups Into U.S., Inaugural Global Healthcare In... » Read More BioCommercialization, a resource for professionals who translate research innovations into developed products available at biocommercialization.com.
Presenter, ABCs of Commercialization, 6th Corn Utilization and Technology Conference, Kansas City, Missouri (June 3, 2008).
Presenter, Opportunities in Emerging Geographies, 2nd Annual Global Healthcare Investing Conference, Cleveland, Ohio (April 30, 2008).
Interviewed for feature segment related to biotechnology commercialization and pharmaceutical commercialization, Conversation with Lee Presser (television broadcast September 10 & 17, 2007).
Presenter, Bringing Overseas Start-Ups Into U.S., Inaugural Global Healthcare Investing Conference, Cleveland, Ohio (June 21, 2007).
Presenter, Leveraging the Revenue Potential of Patents Through Commercialization, Mumbai, India (November 27, 2006).
Presenter, Streamlining AgBio Regulation - Shifting Public Policy and Statutory Design for Multi-Trait and Predictably Expressed Gene Packages, Second Generation Ag Biotech Conference, Washington, D.C. (March 16, 2005).
Co-author, Standing at the Molecular Crossroads: Report on Nanotechnology in Missouri, White Paper requested by the Missouri Department of Economic Development (September, 2003).
Co-author, Attack of the Clones
and the Issues of Clones, 3 Colum. Sci. & Tech. L. Rev. 3 (May, 2002), available at stlr.org/cite.cgi?volume=3&article=3.
Co-presenter, Full, Clear, Concise and Exact. What You Should Know About the Patent Written Description Requirement: A Practitioner's Roundtable, Bar Association of Metropolitan St. Louis (February 26, 2002).
»Read Less |
BioCommercialization, a resource for professionals who translate research innovations into developed products available at biocommercialization.com.
Presenter, ABCs of Commercialization, 6th Corn Utilization and Technology Conference, Kansas City, Missouri (June 3, 2008).
Presenter, Opportunities in Emerging Geographies, 2nd Annual Global Healthcare Investing Conference, Cleveland, Ohio (April 30, 2008).
Interviewed for feature segment related to biotechnology commercialization and pharmaceutical commercialization, Conversation with Lee Presser (television broadcast September 10 & 17, 2007).
Presenter, Bringing Overseas Start-Ups Into U.S., Inaugural Global Healthcare Investing Conference, Cleveland, Ohio (June 21, 2007).
Presenter, Leveraging the Revenue Potential of Patents Through Commercialization, Mumbai, India (November 27, 2006).
Presenter, Streamlining AgBio Regulation - Shifting Public Policy and Statutory Design for Multi-Trait and Predictably Expressed Gene Packages, Second Generation Ag Biotech Conference, Washington, D.C. (March 16, 2005).
Co-author, Standing at the Molecular Crossroads: Report on Nanotechnology in Missouri, White Paper requested by the Missouri Department of Economic Development (September, 2003).
Co-author, Attack of the Clones
and the Issues of Clones, 3 Colum. Sci. & Tech. L. Rev. 3 (May, 2002), available at stlr.org/cite.cgi?volume=3&article=3.
Co-presenter, Full, Clear, Concise and Exact. What You Should Know About the Patent Written Description Requirement: A Practitioner's Roundtable, Bar Association of Metropolitan St. Louis (February 26, 2002).
|
 |
